甲胺与硫类尿素对2型糖尿病女性异常长寿的比较有效性:目标试验仿真
Aladdin H Shadyab1,2, Mark A Espeland3,4, Andrew O Odegaard5
1Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA.
概括
与硫氨酸urea相比,在患有2型糖尿病的女性中,梅特福林的启动可能会增加异常长寿. 这项研究表明,对长期生存有潜在的益处,尽管因果关系需要进一步调查.
科学领域:
- 内分泌学 在内分泌学.
- 老年学是指老年学的学科.
- 药学流行病学 药学流行病学
背景情况:
- 甲福明和死亡结果之间的关联是不一致的.
- 没有研究研究过甲福明与异常长寿 (存活到90岁或以上) 的联系.
研究的目的:
- 确定是否开始服用甲福明与2型糖尿病女性的异常寿命相比,与硫基尿素相关.
主要方法:
- 一个新用户,积极的比较者队列研究,使用目标试验仿真在妇女健康倡议.
- 包括60岁以上的女性,患有2型糖尿病,开始单独治疗甲胺或硫氨酸尿素.
- 使用1:1的倾向得分匹配来平衡混因素.
主要成果:
- 在438名匹配女性中,甲福明的开始与90岁前死亡的发病率较低 (每100人年3.7%) 与硫氨酸urea (每100人年5.0) 相比.
- 与硫基尿素 (HR,0.70;95% CI,0.56-0.88) 相比,开始服用甲胺与90岁前死亡的调整后风险降低了30%相关.
结论:
- 与2型糖尿病女性相比,开始服用甲胺与异常长寿的增加有关.
- 不能推断因果关系,因为观察设计和缺乏安慰剂比较在这个试验模拟.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
168
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
168
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Oral Hypoglycemic Agents: Glinides
116
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
116
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Comparing the Survival Analysis of Two or More Groups
107
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
107
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K


